Sign in →

Test ID IBDP Inflammatory Bowel Disease Serology Panel, Serum

Useful For

As an adjunct in the diagnosis of ulcerative colitis and Crohns disease in patients suspected of having inflammatory bowel disease

Profile Information

Test ID Reporting Name Available Separately Always Performed
AASCA Saccharomyces cerevisiae Ab, IgA, S Yes Yes
GASCA Saccharomyces cerevisiae Ab, IgG, S Yes Yes
NSA Neutrophil Specific Antibodies No Yes

Method Name

AASCA, GASCA: Enzyme-Linked Immunosorbent Assay (ELISA)

NSA: Indirect Immunofluorescent Assay (IFA)

Reporting Name

Inflammatory Bowel Disease Panel, S

Specimen Type

Serum

Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 0.5 mL

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 21 days
  Frozen  21 days

Clinical Information

The term "inflammatory bowel disease" (IBD) is often used to refer to 2 diseases, ulcerative colitis (UC) and Crohn's disease (CD), that  produce inflammation of the large or small intestines. The diagnosis of these 2 diseases is based on clinical features, the results of barium X-rays, colonoscopy, mucosal biopsy histology, and in some cases operative findings and resected bowel pathology and histology.

 

Recently, patients with IBD have been shown to have antibodies in serum that help to distinguish between CD and UC.(1) Patients with UC often have measurable neutrophil specific antibodies (NSA), which react with as yet uncharacterized target antigens in human neutrophils; whereas, patients with CD often have measurable antibodies of the IgA and/or IgG isotypes, which react with cell wall mannan of Saccharomyces cerevisiae strain Su 1.

Reference Values

Saccharomyces cerevisiae ANTIBODY, IgA

Negative: ≤20.0 U

Equivocal: 20.1-24.9 U

Weakly positive: 25.0-34.9 U

Positive: ≥35.0 U

 

Saccharomyces cerevisiae ANTIBODY, IgG

Negative: ≤20.0 U

Equivocal: 20.1-24.9 U

Weakly positive: 25.0-34.9 U

Positive: ≥35.0 U

 

NEUTROPHIL-SPECIFIC ANTIBODIES

Negative (not detectable)

Cautions

Results from this test should not be exclusively relied upon to establish the diagnosis of ulcerative colitis (UC) or Crohn's disease (CD) or to distinguish between these 2 diseases. Some patients with CD have detectable neutrophil specific antibodies (NSA), and some patients with UC have elevated levels of IgA and/or IgG anti-Saccharomyces cerevisiae antibodies (ASCA).

 

Approximately one third of patients have low titered anti-nuclear antibodies (ANA), which make it impossible to distinguish the presence or absence of NSA. These results are reported as indeterminate.

 

Not useful to determine the extent of disease in patients with inflammatory bowel disease (IBD) or determine the response to disease-specific therapy including surgical resection of diseased intestine.

Day(s) Performed

Varies

Report Available

Same day/1 day

Performing Laboratory

Mayo Medical Laboratories in Rochester

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions.

CPT Code Information

86255

86671 x 2

NY State Approved

Yes